Description:

Almost 20% of US adults have OSA and the prevalence is growing with the obesity epidemic. OSA doubles the risk of cardiac death and stroke and increases vascular mortality fivefold. Capri's mission is to make the most effective OSA treatment ACCESSIBLE to everybody. Since our incorporation, we have developed a novel approach to inject neurostimulation implants & leads. This approach changes the OSA business landscape by disrupting an existing large surgical market. Our main competitor has a $6B market cap and achieved $803M in revenue in 2024 and projecting $950M in revenue in 2025 and a 25% growth rate. In 2024 our main competitor is still only penetrated 7% of the annual USA market. Current solutions require a 2-hour long procedure, performed under general anaesthetic. The Capri procedure is a 20-minute procedure, performed under local anaesthetic. Our injectable approach moves procedures out of the operating room and into clinics and offices, significantly increasing patient access and reducing overall cost of treatment.